RYTM Quote, Financials, Valuation and Earnings

MannKind has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 16.48%. Rhythm Pharmaceuticals's return on equity of -208.96% beat MannKind's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.08%. On the other hand MannKind has an analysts' consensus of $9.25 which suggests that it could grow by 52.41%. Given that MannKind has higher upside potential than Rhythm Pharmaceuticals, analysts believe MannKind is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison MannKind has a beta of 1.289, suggesting its more volatile than the S&P 500 by 28.87%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than MannKind quarterly revenues of $70.1M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than MannKind's net income of $11.6M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while MannKind's PE ratio is 80.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.05x versus 6.93x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -49.65%. Rhythm Pharmaceuticals's return on equity of -208.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.08%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 519.8%. Given that NovaBay Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.05x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 4.63%. Rhythm Pharmaceuticals's return on equity of -208.96% beat TG Therapeutics's return on equity of -8.4%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.08%. On the other hand TG Therapeutics has an analysts' consensus of $38.67 which suggests that it could grow by 35.38%. Given that TG Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe TG Therapeutics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.245, suggesting its more volatile than the S&P 500 by 124.477%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than TG Therapeutics quarterly revenues of $83.9M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than TG Therapeutics's net income of $3.9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 39.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.05x versus 17.69x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -36.72%. Rhythm Pharmaceuticals's return on equity of -208.96% beat Voyager Therapeutics's return on equity of 9.12%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.08%. On the other hand Voyager Therapeutics has an analysts' consensus of $17.10 which suggests that it could grow by 201.59%. Given that Voyager Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.053%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than Voyager Therapeutics quarterly revenues of $24.6M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than Voyager Therapeutics's net income of -$9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 8.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.05x versus 1.93x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.